ライフサイエンスコーパス: valganciclovir

1 oraneously compounded liquid formulations of valganciclovir.

2 nsisted of ganciclovir followed by 1 year of valganciclovir.

3 receiving either ganciclovir or its prodrug valganciclovir.

4 r and 160 days in the group assigned to oral valganciclovir.

5 ived consolidation high-dose zidovudine with valganciclovir.

6 s included trimethoprim-sulfamethoxazole and valganciclovir.

7 patients received universal prophylaxis with valganciclovir.

8 ematologic toxicity directly associated with valganciclovir.

9 the incidence of CMV disease and toxicity of valganciclovir.

10 ctiveness of 6- versus 3-mo prophylaxis with valganciclovir.

11 novel activating enzyme for valacyclovir and valganciclovir.

12 ous ganciclovir (7.5-10 mg/kg/12 hr) or oral valganciclovir (1350-1800 mg/12 hr) corrected according

13 s and outcomes of prolonged prophylaxis with valganciclovir (200 vs. 100 days) in a cohort of 10,000

14 Of the 500 patients (295 ganciclovir, 205 valganciclovir), 22 patients (4.4%) developed CMV diseas

15 s used were ganciclovir (100% and 96.2%) and valganciclovir (23.1%) and the second-line agent was fos

16 h either valaciclovir 500 mg orally daily or valganciclovir 450 mg orally twice daily.

17 thirty-seven high-risk RTR (low-dose group = valganciclovir 450 mg/day [n = 130]; high-dose group = v

18 f oral ganciclovir (3 g/day) versus low-dose valganciclovir (450 mg/day) for CMV prophylaxis.

19 Three months of low-dose valganciclovir (450 mg/day) was as effective as ganciclo

20 er baseline were treated with ganciclovir or valganciclovir (5 mg/kg or 900 mg twice daily, respectiv

21 A higher proportion of patients who received valganciclovir (64.7%) belonged to the high-risk group (

22 (10.0 percent) and 7 of 71 assigned to oral valganciclovir (9.9 percent) had progression of cytomega

23 <350 cells/mm(3) were randomized to receive valganciclovir 900 mg daily or placebo for 8 weeks, foll

24 corticosteroids and anti-CMV treatment (oral valganciclovir 900 mg twice daily, topical ganciclovir 0

25 ovir 450 mg/day [n = 130]; high-dose group = valganciclovir 900 mg/day [n = s7]) were evaluated for 1

26 nged cytomegalovirus (CMV) prophylaxis using valganciclovir 900 mg/day, some centers use 450 mg/day d

27 orally every 6 hours) and the oral prodrug, valganciclovir (900 mg orally every 12 hours).

28 6 months of valganciclovir (900 mg/d) or placebo.

29 We conducted a clinical trial of oral valganciclovir, a drug with in vitro activity against Ka

30 The median dose of oral valganciclovir administered in the present trial was 16

31 HHV-8 were randomized to receive 8 weeks of valganciclovir administered orally (900 mg once per day)

32 Valganciclovir administered orally once per day is well

33 Fourteen participants were randomized to valganciclovir and 16 to placebo.

34 k for late CMV disease (95 patients received valganciclovir and 89 received placebo).

35 MV disease in heart transplant patients, and valganciclovir and CMV immune globulin reduce rejection

36 ess of 6-mo prophylaxis over a wide range of valganciclovir and hospital costs, as well as variation

37 In a large randomized trial comparing oral valganciclovir and intravenous ganciclovir for treatment

38 luate prolonged prophylaxis of 200 days with valganciclovir and its long-term economic impact.

39 in the antigenemia level after initiation of valganciclovir and oral ganciclovir was 80.5% versus 50.

40 s under the curve (AUCs) of ganciclovir from valganciclovir and oral ganciclovir were 46.3 +/- 15.2 a

41 tations confer resistance to ganciclovir and valganciclovir, and a UL54 mutation confers multidrug re

42 Orally administered valganciclovir appears to be as effective as intravenous

43 Ganciclovir and valganciclovir are highly effective antiviral drugs with

44 ravenous ganciclovir and, increasingly, oral valganciclovir are now considered the mainstay of treatm

45 tions of sustained-release implants and oral valganciclovir are unavailable or prohibitively expensiv

46 After four weeks, all patients received valganciclovir as maintenance therapy.

47 Antigenemia-directed valganciclovir as preemptive therapy seems to be effecti

48 m 2001 to 2004 with antigenemia who received valganciclovir as preemptive therapy were compared with

49 High-dose ganciclovir/valganciclovir can be an option in the treatment of resi

50 toxic therapy using high-dose zidovudine and valganciclovir, can control symptoms and decrease adenop

51 In summary, 6-mo prophylaxis with valganciclovir combined with a one-time determination of

52 all patients of antiviral drugs (ganciclovir/valganciclovir) combined with anti-CMV Ig for 4 weeks.

53 that prolonged prophylaxis of 200 days with valganciclovir compared with 100 days significantly redu

54 ly continuous intravenous infusions and oral valganciclovir compared with bilateral treatments.

55 Prophylaxis was 2 x 450 mg oral valganciclovir/day for 100 days; preemptive patients wer

56 fter a positive PCR test received 2 x 900 mg valganciclovir/day for at least 14 days followed by seco

57 counts at months 5 and 6; however, premature valganciclovir discontinuation rates were similar.

58 tes after transplantation (NODAT), premature valganciclovir discontinuation, renal function and myelo

59 Valganciclovir dosage was adjusted according to renal fu

60 These findings suggest that in the valganciclovir era, cytomegalovirus serostatus of both d

61 None of the 20 patients randomized to valganciclovir experienced CMV reactivation (P = .004).

62 ant recipients who have received 3 months of valganciclovir, extending prophylaxis by an additional 9

63 al transplant centers used prophylactic oral valganciclovir for 3 months posttransplant in the D+R- t

64 ting symptomatic congenital CMV disease with valganciclovir for 6 months, as compared with 6 weeks, d

65 2006 and December 2006 received prophylactic valganciclovir for 90 days after transplant, and those t

66 trimoxazole, itraconazole, and aciclovir (or valganciclovir for asymptomatic cytomegalovirus viremia)

67 atment with intravenous ganciclovir and oral valganciclovir for cytomegalovirus (CMV) disease in soli

68 wo patients received preemptive therapy with valganciclovir for individual episodes of replication.

69 lowing oral administration of ganciclovir or valganciclovir for prophylaxis of cytomegalovirus (CMV)

70 axis with valacyclovir (n=34) or pre-emptive valganciclovir for significant CMV viremia detected at p

71 ynergistic with that of other agents such as valganciclovir for treating cytomegalovirus infection.

72 ncy virus-seronegative participants received valganciclovir for up to six 4-week cycles at doses used

73 for preventing or treating CMV: ganciclovir, valganciclovir, foscarnet, and cidofovir.

74 ld increase over baseline was reduced in the valganciclovir group (11% vs. 36%; P < 0.001).

75 received hematopoietic growth factors in the valganciclovir group (25.3% vs. 12.4%; P = 0.026).

76 ented in 47.1% (8/17) of the patients in the valganciclovir group and 28.6% (6/21) of the patients in

77 s and patient outcome did not differ for the valganciclovir group versus the oral ganciclovir group o

78 ovir and 46 of 64 (71.9 percent) assigned to valganciclovir had a satisfactory response to induction

79 important enzyme activating valacyclovir and valganciclovir in humans and an important new target for

80 Valganciclovir is an orally administered prodrug that is

81 rsatile by data suggesting oral therapy with valganciclovir is not inferior to intravenous therapy wi

82 evidence for oral anti-CMV prophylaxis using valganciclovir is presented, together with a summary of

83 Trials of galantamine, hydrocortisone, IgG, valganciclovir, isoprinosine, fluoxetine, and various co

84 n controlling active disease is limited, but valganciclovir may have a role as maintenance therapy in

85 Low-dose valganciclovir may provide a significant cost avoidance

86 9 additional months of oral valganciclovir (n = 70) or placebo (n = 66).

87 Further investigations into the impact of valganciclovir on EBV-associated diseases are needed.

88 We evaluated the effects of valganciclovir on oral EBV shedding in a randomized, dou

89 ed by either intravenous ganciclovir or oral valganciclovir once daily until hospital discharge (n =

90 Twenty-six men received oral valganciclovir or daily placebo for 8 weeks, followed by

91 solid organ transplant recipients receiving valganciclovir or ganciclovir in an international multic

92 r CMV using antiviral agents (typically oral valganciclovir or intravenous ganciclovir) is now almost

93 ant recipients who received prophylaxis with valganciclovir or oral ganciclovir for 100 days.

94 he study drug they had not yet taken (either valganciclovir or placebo), for 8 additional weeks.

95 ments were performed after administration of valganciclovir oral solution and of intravenous ganciclo

96 tes with symptomatic congenital CMV disease, valganciclovir oral solution provides plasma concentrati

97 e ganciclovir patients (5.4%) and six of the valganciclovir patients (2.9%) developed CMV disease (P=

98 increasing durations of 5-fluorocytosine and valganciclovir prodrug therapy and conventional-dose thr

99 ients were administered 5-fluorocytosine and valganciclovir prodrug therapy for 1 (cohorts 1-3), 2 (c

100 Valganciclovir prophylactic treatment seemed to delay, b

101 renal transplant patients receiving 24 weeks valganciclovir prophylaxis (15 mg/kg/day, maximum 900 mg

102 kidney and/or pancreas transplants received valganciclovir prophylaxis for either 3 or 6 mo during t

103 characterized viral genotypes in the 200-day valganciclovir prophylaxis group showed no evidence of a

104 tion (IMPACT) comparing 200 with 100 days of valganciclovir prophylaxis in 318 cytomegalovirus D+/R-

105 ety of 6 months of low-dose versus high-dose valganciclovir prophylaxis in high-risk, donor-positive/

106 usted life year (QALY) suggests that 200-day valganciclovir prophylaxis is cost effective over the 10

107 Oral valganciclovir prophylaxis significantly reduces CMV inf

108 Valganciclovir prophylaxis significantly reduces disease

109 Valganciclovir prophylaxis was not superior in reducing

110 63 patients who received oral ganciclovir or valganciclovir prophylaxis.

111 was low, especially in patients who received valganciclovir prophylaxis.

112 ely for CMV infection, compared with primary valganciclovir prophylaxis.

113 primary composite outcome occurred in 20% of valganciclovir recipients versus 21% of placebo-preempti

114 Valganciclovir reduced oropharyngeal shedding of cytomeg

115 Valganciclovir reduced the proportion of days with EBV d

116 Prolonged prophylaxis with valganciclovir reduces the incidence of events associate

117 Low-dose and high-dose valganciclovir regimens provide similar efficacy in prev

118 llected from participants who were receiving valganciclovir (relative risk [RR], 0.54 [95% confidence

119 ed placebo, though participants who received valganciclovir reported more days of diarrhea.

120 Both prophylactic and preemptive oral valganciclovir therapy are effective for the management

121 ed a randomized, placebo-controlled trial of valganciclovir therapy in neonates with symptomatic cong

122 d with valacyclovir prophylaxis, pre-emptive valganciclovir therapy may lead to less severe interstit

123 prophylaxis, defined as the continuation of valganciclovir to prevent relapse after the successful t

124 ebo-treated participants, but in none of the valganciclovir-treated participants (P = .007).

125 Valganciclovir-treated participants had significantly gr

126 crog.h/ml, AUCs typical of those achieved in valganciclovir-treated patients.

127 scontinuation of prophylaxis, recovered with valganciclovir treatment and did not experience subseque

128 raviolet-inactivated virus had no effect and valganciclovir treatment showed that late gene expressio

129 dies suggest that extending prophylaxis with valganciclovir up to 12 months is clearly beneficial for

130 In the D+/R- group, valganciclovir usage was associated with a decreased ris

131 Valganciclovir use in children was effective as prophyla

132 Median duration of valganciclovir use was 5.9 months (range 0.5-24 months).

133 The efficacy of valganciclovir used as preemptive therapy for cytomegalo

134 4 days of pretransplant donor treatment with valganciclovir (valG) versus placebo reduced donor-to-re

135 The availability of valganciclovir (VGCV) has significantly simplified the t

136 Valganciclovir (VGCV) is commonly utilized for CMV proph

137 he impact of antiviral chemoprophylaxis with valganciclovir (VGCV) or ganciclovir (GCV) on CMV replic

138 The bioavailability of valganciclovir was 41.1%.

139 ystemic exposure to ganciclovir delivered by valganciclovir was associated with delayed development o

140 Although valganciclovir was not active against KS in this setting

141 Valganciclovir was the most common antiviral used, with

142 Valganciclovir was tolerated without side effects or leu

143 fetil (MMF), and rapidly tapered prednisone; valganciclovir was used for CMV prophylaxis.

144 Doses of ganciclovir or valganciclovir were low in 10 (26%) of 39 at some time b

145 ydrolytic activity for both valacyclovir and valganciclovir with specificity constants (kcat/Km), 420

146 We compared the effects of oral valganciclovir with those of intravenous ganciclovir as

147 ntiviral agents (acyclovir, ganciclovir, and valganciclovir) with outcomes in high-risk recipients (D

148 venous ganciclovir followed by two months of valganciclovir); with standard prophylaxis (n = 45, intr